Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Combination therapeutics for the world's toughest diseases
Olio Labs has raised $9.0M across 2 funding rounds.
Key people at Olio Labs.
Olio Labs was founded in 2023 by Tom Roseberry (Founder) and David Tingley (Founder).
Olio Labs has raised $9.0M in total across 2 funding rounds.
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.
Key people at Olio Labs.
Olio Labs is a biotechnology company founded in 2023 that develops combination therapeutics using artificial intelligence (AI) and machine learning to address complex diseases. Unlike traditional drug discovery that targets one or two proteins, Olio Labs’ platform considers the thousands of interacting proteins in the human body to design more effective and safer treatment combinations. Their AI-powered platform automates the discovery process, enabling rapid *in silico* testing of trillions of potential drug combinations to identify the most promising candidates for further development. This approach aims to solve the challenge of side effects and limited efficacy seen in single-target drugs by optimizing multi-target therapies[1][2][4].
As a portfolio company, Olio Labs serves pharmaceutical developers and healthcare innovators focused on the world’s toughest diseases, providing a novel therapeutic design platform that accelerates drug discovery and improves treatment outcomes. The company has demonstrated growth momentum with a recent $4.5 million funding round led by Boom Capital and Overwater Ventures, supported by notable investors including Y Combinator and Scrum Ventures. Their advisory board features experienced industry leaders, underscoring their strong scientific and commercial foundation[1][2].
Olio Labs was founded in 2023 in San Francisco by David Tingley and Tom (last name not specified), both systems neuroscientists with backgrounds in computational biology. They previously collaborated on the Computational Biology team at Loyal for Dogs, leveraging advanced research tools to manipulate single neurons. Recognizing the limitations of current drug discovery methods that cannot precisely target complex protein interactions in humans, they envisioned a computational platform to automate and optimize combination therapeutics. Their unique blend of scientific expertise and engineering skills enabled them to build a platform that bridges experimental biology and AI-driven modeling, aiming to revolutionize drug development[2][1].
Early traction included the development of lead therapeutic combinations that outperform existing market-leading drugs, validating their approach. The company quickly attracted seed funding and industry veterans to its advisory board, setting the stage for rapid growth and platform expansion[1].
Olio Labs is riding the convergence of AI and biotechnology, a transformative trend reshaping drug discovery. The timing is critical as traditional pharmaceutical R&D faces high costs, long development cycles, and frequent failures. AI-driven platforms like Olio Labs’ enable exploration of vast combinatorial spaces that were previously impossible to test experimentally, addressing a major bottleneck in developing effective multi-target therapies.
Market forces such as increasing demand for precision medicine, advances in computational biology, and growing acceptance of AI in healthcare favor Olio Labs’ approach. By automating and optimizing combination therapeutics, the company influences the broader ecosystem by setting new standards for drug discovery efficiency and therapeutic design sophistication[1][2].
Looking ahead, Olio Labs is poised to expand its platform across multiple disease indications, leveraging its AI capabilities to accelerate the pipeline of combination therapeutics. Trends such as personalized medicine, integration of real-world biological data, and regulatory openness to AI-designed drugs will shape their trajectory.
Their influence may grow from a niche AI drug discovery startup to a key player driving systemic change in how complex diseases are treated, potentially reducing side effects and improving patient outcomes globally. Continued funding, strategic partnerships, and clinical validation of their lead candidates will be critical milestones to watch.
Olio Labs exemplifies the new wave of biotech companies harnessing AI not just to speed up drug discovery but to fundamentally rethink therapeutic design for the world’s toughest diseases[1][2][4].
Olio Labs has raised $9.0M across 2 funding rounds. Most recently, it raised $5.0M Series U in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2025 | $5M Series U | — | Overwater Ventures | Announced |
| Jul 1, 2023 | $4M Seed | — | Pioneer Fund, Y Combinator, Zaka Ventures | Announced |
Olio Labs was founded in 2023 by Tom Roseberry (Founder) and David Tingley (Founder).
Olio Labs has raised $9.0M in total across 2 funding rounds.
Olio Labs's investors include Overwater Ventures, Pioneer Fund, Y Combinator, ZAKA Ventures.
